Roche Holding AG Stock News

Pfizer's revenue has taken a big hit because of lower COVID-19-related sales. Roche just released third-quarter earnings.

Roche (RHHBY) reports a sales decline in the first nine months of 2023 as COVID-19-test sales continue to dent its top line. Currency rate fluctuations also impact its results.

Roche stock skidded early Thursday after the Swiss drugmaker said declining demand for Covid products weighed on third-quarter sales.

Roche said nine-month sales slipped 6% to 44.1 billion Swiss francs ($49.1 billion), hit by a sharp decline in sales of COVID-19 products and as a strong Swiss franc weighed on the value of overseas s

Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.

Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four months in phase III studies for retinal vein occlusion.

Basel, 02 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new data for OCREVUS® (ocrelizumab) and investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib for multiple scl

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new data for Ocrevus® (ocrelizumab) and investigational Bruton's tyrosi

Biogen Inc. BIIB, -0.32% said late Friday the Food and Drug Administration approved its biosimilar version of Roche ROG, +0.30% ‘s arthritis treatment Actemra. Biogen said its treatment Tofidence, o

Pakistan's drug regulator said on Monday it had temporarily banned the use of a cancer medication distributed by Swiss pharmaceutical company Roche pending an investigation, as 12 patients went blind

Roche's stock price has declined, underperforming its peers, due to the loss of patent protection for its blockbuster drugs, lower Covid-related revenue and several pipeline setbacks. The company has

The pharmaceutical industry is one of the most dynamic and innovative sectors in the world. It is constantly developing new drugs and treatments to address various health challenges and improve the qu

Roche is open to making big acquisitions if they make "sense", Chief Executive Thomas Schinecker said, with the Swiss drugmaker unencumbered by its $20.7 billion deal last year to buy back its shares

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th

Roche (RHHBY) biologics license application seeking approval for crovalimab for paroxysmal nocturnal hemoglobinuria gets FDA acceptance.